StarTric is excited to announce a successful funding round that raised $2,500,000 to further advance its groundbreaking structural heart technology. Developing an innovative, minimally invasive repair device specifically for tricuspid regurgitation (TR), StarTric is leading the way as the first transcatheter replica of the effective open surgery Clover repair technique. This funding marks a significant milestone in our journey to transform the treatment landscape for a disease that affects nearly 70 million people worldwide, with up to 85% mortality over 10 years if left untreated. With TR severely reducing oxygenation and quality of life and leading to complications like atrial fibrillation and heart failure, our device promises to become a safer and more accessible alternative for the vast majority of patients who currently cannot undergo high-risk open heart surgery.
Grounded in a rich legacy of innovation—co-founded by prominent figures such as Prof. Ottavio Alfieri, who introduced the “Alfieri-stitch,” and Prof. Michele De Bonis, pioneers of the Clover technique—StarTric’s transcatheter device has been extensively prototyped and validated in both in-vivo and ex-vivo pathological models. Final product development is well underway, and this funding boost will be instrumental in propelling clinical trials, refining device performance, and ultimately making this life-changing technology available to a broader patient population. This investment not only solidifies our commitment to addressing a critical healthcare need but also positions StarTric at the forefront of next-generation cardiovascular treatments, paving the way for a safer, more effective future in the management of tricuspid regurgitation.
Disclaimer: StarTric is currently under development and not available for clinical use.
.png&w=3840&q=75)
